Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography

Biomedical Chromatography

Volumn 19, Issue 10, 2005, Pages 777-782

  Cheremina, Olga ^a   Bachmakov, Iouri ^a   Neubert, Antje ^a   Brune, Kay ^a   Fromm, Martin F ^a   Hinz, Burkhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Noroxycodone; Oxycodone; Pharmacokinetics; Reversed phase HPLC; UV detection

Indexed keywords

BIOMOLECULES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES; PLASMA (HUMAN);

HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMAS; LIQUID-LIQUID EXTRACTION; NOROXYCODONE; OPIOID RECEPTORS; OXYCODONE; REVERSED PHASE HPLC; REVERSED-PHASE HPLC METHOD; SIMULTANEOUS DETERMINATIONS; UV DETECTION;

PHARMACOKINETICS;

ACETONITRILE; BUFFER; CODEINE; DRUG METABOLITE; OXYCODONE; PHOSPHATE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RADIATION DETECTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ANALYSIS; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 29544437007     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.516     Document Type: Article

References (31)

1. Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE and Fitzmartin RD. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. Journal of Pain and Symptom Management 1997; 13: 75-82.
2. Bostrom E, Jansson B, Hammarlund-Udenaes M and Simonsson US. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue. Rapid Communications in Mass Spectrometry 2004; 18: 2565-2576.
3. Curtis GB, Jonson GH, Clark P, Taylor R, Brown J, O'Callaghan R, Shi M and Lacouture PG. Relative potency of controlled-release morphine in a postoperative pain model. European Journal of Clinical Pharmacology 1999; 55: 425-429.
4. Dawson M, Fryirs B, Kelly T, Keegan J and Mather LE. A rapid and sensitive high-performance liquid chromatography-electrospray ionisation-triple quadrupole mass spectrometry method for the quantification of oxycodone in human plasma. Journal of Chromatographic Science 2002; 40: 40-44.
5. De Conno F, Ripamonti C, Sbanotto A, Barletta L, Zecca E, Martini C and Ventafridda V. A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine and pentazocine in cancer pain. Journal of Pain and Symptom Management 1991; 6: 423-427.
6. Gebauer MG, McClure AF and Vlahakis TL. Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel. International Journal of Pharmacy 2001; 223: 49-54.
7. Glare PA and Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. Journal of Clinical Oncology 1993; 11: 973-978.
8. Heiskanen T, Olkkola KT and Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clinical Pharmacology and Therapeutics 1998; 64: 603-611.
9. Ishida T, Oguri K and Yoshimura H. Determination of oxycodone metabolites in urines and feces of several mammalian species. Journal of Pharmacobiodynamics 1982; 5: 521-525.
10. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF and Goldenheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clinical Pharmacology and Therapeutics 1996; 59: 52-61.
11. Kalso E and Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics 1990; 47: 639-646.
12. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I and Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiologica Scandinavica 1991; 35: 642-646.
13. Kokki H, Rasanen I, Reinikainen M, Suhonen P, Vanamo K and Ojanpera I. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clinical Pharmacokinetics 2004; 43: 613-622.
14. Lalovic B, Phillips B, Risler LL, Howald W and Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition 2004; 32: 447-454.
15. Leow KP and Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Science 1994; 54: 1229-1236.
16. Leow KP, Smith MT, Williams B and Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology and Therapeutics 1992; 52: 487-495.
17. Mandema JW, Kaiko RF, Oshlack B, Reder RF and Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. British Journal of Clinical Pharmacology 1996; 42: 747-756.
18. Meatherall R. GC-MS confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine. Journal of Analytical Toxicology 1999; 23: 177-186.
19. Menelaou A, Hutchinson MR, Quinn I, Christensen A and Somogyi AA. Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technology in Biomedicine and Life Science 2003; 785: 81-88.
20. Nuutinen LS, Wuolijoki E and Pentikeinen IT. Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial. Acta Anaesthesiologica Scandinavica 1986; 30: 620-624.
21. Olkkola KT, Hamunen K, Seppala T and Maunuksela EL. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. British Journal of Clinical Pharmacology 1994; 38: 71-76.
22. Orton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE and Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clinical Pharmacology and Therapeutics 1993; 54: 463-472.
23. Poyhia R, Seppala T, Olkkola KT and Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British Journal of Clinical Pharmacology 1992; 33: 617-621.
24. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
25. Silvasti M, Rosenberg P, Seppala T, Svartling N and Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiologica Scandinavica 1998; 42: 576-580.
26. Sindrup SH and Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
27. Smith MT, Watt JA, Mapp GP and Cramond T. Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. Therapeutic Drug Monitoring 1991; 13: 126-130.
28. Smith ML, Hughes RO, Levine B, Dickerson S, Darwin WD and Cone EJ. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. Journal of Analytical Toxicology 1995; 19: 18-26.
29. Watson CP and Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-1841.
30. Weinstein SH and Gaylord JC. Determination of oxycodone in plasma and identification of a major metabolite. Journal of Pharmaceutical Science 1979; 68: 527-528.
31. Wright AW, Lawrence JA, Iu M, Cramond T and Smith MT. Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. Journal of Chromatography B: Biomedical Science Applications 1998; 712: 169-175.